Intensity Therapeutics Inc. (NASDAQ:INTS) Sees Significant Drop in Short Interest

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 68,355 shares, a drop of 58.0% from the July 15th total of 162,597 shares. Based on an average daily trading volume, of 23,378 shares, the short-interest ratio is currently 2.9 days. Approximately 2.7% of the company’s stock are sold short.

Intensity Therapeutics Stock Performance

INTS traded down $0.04 during midday trading on Friday, hitting $3.96. 38,949 shares of the company traded hands, compared to its average volume of 26,156. Intensity Therapeutics has a 52 week low of $3.51 and a 52 week high of $43.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 4.86. The company’s 50-day moving average is $4.25 and its 200 day moving average is $5.55.

Intensity Therapeutics (NASDAQ:INTS) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). Sell-side analysts predict that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of INTS. Geode Capital Management LLC grew its stake in shares of Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares during the period. State Street Corp increased its position in shares of Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares during the last quarter. Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter worth approximately $41,000. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter worth approximately $26,000. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in shares of Intensity Therapeutics by 25.5% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after buying an additional 51,000 shares during the last quarter. 3.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on INTS. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.